Influenza Hemagglutinin (HA) Peptide
(Synonyms: H-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-OH) 目录号 : GP10152
A peptide
Cas No.:92000-76-5
Sample solution is provided at 25 µL, 10mM.
HA tag,Complexes containing plasmid DNA, transferrin-polylysine conjugates, and polylysine-conjugated peptides derived from the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2 have been used for the transfer of luciferase or -galactosidase marker genes to K562 cells, HeLa cells, and BNL CL.2 hepatocytes. The presence of these influenza peptide conjugates in the DNA complexes renders the complexes active in membrane disruption in a liposome leakage assay and results in a substantial augmentation of the transferrin-polylysine-mediated gene transfer.
Fusogenic peptides derived from the N-terminal sequence of the influenza virus hemagglutinin subunit HA-2 is part of the DNA complexes and the resulting augmentation of gene transfer to cultured cells1.
In the influenza virus, the hemagglutinin (HA) protein mediates both binding of the virus to the cell surface and the subsequent fusion of viral and cellular membranes. HA is composed of a receptor-binding subunit, denoted HA1, and a fusogenic subunit, denoted HA2. The native HA1yHA2 complex, as found on the surface of the native virus, is fusioninactive. For influenza virus, membrane fusion is regulated by the conformational state of the hemagglutinin (HA) protein, which switches from a native (nonfusogenic) structure to a fusion-active (fusogenic) conformation when exposed to the acidic environment of the cellular endosome. The native structure of HA is trapped in a metastable state and that the fusogenic conformation is released by destabilization of native structure2.
References:
1. E. WAGNER, C. PLANK et al, Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle. Proc. Nati. Acad. Sci. USA Vol. 89, pp. 7934-7938, September 1992
2. C. M. CARR, C. CHAUDHRY, P. S. KIM et al. Influenza hemagglutinin is spring-loaded by a metastable native conformation. Proc. Natl. Acad. Sci. USA Vol. 94, pp. 14306–14313
| Cas No. | 92000-76-5 | SDF | |
| 别名 | H-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-OH | ||
| 化学名 | Influenza Hemagglutinin (HA) Peptide | ||
| Canonical SMILES | CC(C)C(C(=O)N1CCCC1C(=O)NC(CC(=O)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(C)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C4CCCN4C(=O)C(CC5=CC=C(C=C5)O)N | ||
| 分子式 | C53H67N9O17 | 分子量 | 1102.15 |
| 溶解度 | ≥ 55.1075mg/mL in DMSO, ≥ 100.4 mg/mL in EtOH, ≥ 46.2 mg/mL in Water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.9073 mL | 4.5366 mL | 9.0732 mL |
| 5 mM | 0.1815 mL | 0.9073 mL | 1.8146 mL |
| 10 mM | 0.0907 mL | 0.4537 mL | 0.9073 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet